Satisfy payer demands for cost-effective medicines

Drugs represent roughly 10 percent of the cost of health care or around $270 billion annually. That has led payers -- including private insurers, Medicare, Medicaid and other government programs -- to require data that demonstrates the cost-effectiveness of a medicine before agreeing to pay for it.

RWE can convincingly provide that data by conducting comparison studies with previously approved medications. The studies are based on claims data along with clinical data generated at the point of care.